Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7044714 | 0.88 | MAPT (0.44) | MAPTKMT2ANPC1RAB9AMAPK1 | |
| SCHEMBL7043415 | 0.87 | MAPK1 (0.44) | MAPTKMT2ANPC1RAB9AMAPK1 | |
| SCHEMBL7035893 | 0.86 | KMT2A (0.43) | MAPTKMT2ANPC1RAB9AMAPK1 | |
| SCHEMBL7045765 | 0.81 | LMNA (0.38) | MAPTKMT2AMAPK1ALDH1A1L3MBTL1 | |
| SCHEMBL7044320 | 0.80 | MAPT (0.62) | MAPTKMT2ANPC1RAB9AMAPK1 | |
| SCHEMBL7045358 | 0.77 | PPIA (0.41) | MAPTNPC1RAB9AMAPK1ALDH1A1 | |
| SCHEMBL6695454 | 0.72 | NPC1 (0.77) | MAPTKMT2ANPC1RAB9AMAPK1 | |
| SCHEMBL7046838 | 0.71 | MAPT (0.49) | MAPTKMT2ANPC1RAB9AMAPK1 | |
| SCHEMBL7043665 | 0.71 | LMNA (0.50) | MAPTKMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL8119258 | 0.71 | MAPT (0.48) | MAPTKMT2ANPC1RAB9AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002064096-A9 | METHODS OF USING PYRIMIDINE-BASED ANTIVIRAL AGENTS | TULARIK INC (US) | 2003-10-16 | — | — | WO | disclosed |
| US-20030130264-A1 | Methods of using pyrimidine-based antiviral agents | TULARIK INC. (US) | 2003-07-10 | — | — | US | disclosed |
| WO-2002064096-A2 | METHODS OF USING PYRIMIDINE-BASED ANTIVIRAL AGENTS | TULARIK INC. (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130264-A1 | Methods of using pyrimidine-based antiviral agents | TYMP, TYMS, NUDT1 | MAPT 2656/4885KMT2A 2560/4885NPC1 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.